← Eichor
Study identifier: NCT04532203 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Condition: Acute Lymphoblastic Leukemia · Non-Hodgkin's Lymphoma  ·  Sponsor: Zhejiang University

PhaseEARLY_Phase 1
Planned participants72
Who can joinAll sexes, 3 Years to 75 Years
Healthy volunteersNo

About this study

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

This description comes directly from the study's public registry record.

Talk to the study team

He Huang, PhD  ·  86-13605714822  ·  hehuangyu@126.com

Yongxian Hu, PhD  ·  86-15957162012  ·  huyongxian2000@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital,College of Medicine, Zhejiang UniversityHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04532203